a chance for a longer life

If your tumor has high levels of PD‑L1, KEYTRUDA is proven to increase your chance of living longer compared to chemotherapy and could be your first treatment option instead of chemotherapy.

A clinical trial compared patients with advanced NSCLC who received KEYTRUDA with those who received chemotherapy containing platinum. All patients in the trial had no previous drug treatment, tested positive for the biomarker PD-L1 at a level of 50% or more, and tested negative for the biomarkers EGFR and ALK. 154 patients received 200 mg of KEYTRUDA every 3 weeks and 151 patients received chemotherapy.

In the trial, KEYTRUDA:

  • KEYTRUDA® (pembrolizumab) Helped Some Patients Live Longer

    Helped some patients live longer

    At the time of patient follow-up, 71% (110 of 154 patients) treated with KEYTRUDA were alive, compared to 58% (87 of 151 patients) treated with chemotherapy; 29% (44 of 154 patients) treated with KEYTRUDA were not alive at follow-up, compared to 42% (64 of 151 patients) treated with chemotherapy.

  • KEYTRUDA® (pembrolizumab) Increased the Chance of Living Without Disease Progression by 50% Compared to Chemotherapy

    Increased the chance of living without disease progression by 50% compared to chemotherapy

    Half of the patients on KEYTRUDA were alive without their cancer spreading, growing, or getting worse at 10.3 months, compared to 6 months for patients on chemotherapy.

  • 45% of patients on KEYTRUDA saw their tumors shrink

    Helped shrink tumors

    45% (69 of 154 patients) on KEYTRUDA had their tumors shrink; 41% (63 of 154 patients) had partial responses and 4% (6 of 154 patients) had complete responses. This is compared to 28% (42 of 151 patients) on chemotherapy who had their tumors shrink; 27% (41 of 151 patients) had partial responses and 1% (2 of 151 patients) had complete responses.

Ask Your Health Care Team if KEYTRUDA® (pembrolizumab) Is Right for You

Ask your health care team if KEYTRUDA is right for you

Want more info about KEYTRUDA?

Sign up for regular updates 

Need help talking to
your doctor?

Download a doctor
discussion guide 

For more information or to sign up over the phone, call 85-KEYTRUDA (855-398-7832)(855-398-7832).

Please scroll for full indication

KEYTRUDA is used to treat a kind of lung cancer called non–small cell lung cancer (NSCLC). KEYTRUDA may be used as your first treatment option when your lung cancer has spread (advanced NSCLC) and tests positive for “PD-L1” and your tumor does not have an abnormal “EGFR” or “ALK” gene.

KEYTRUDA may also be used for advanced NSCLC if you have tried chemotherapy that contains platinum and it did not work or is no longer working and your lung cancer tests positive for PD-L1 and if your tumor has an abnormal EGFR or ALK gene, you have received an EGFR or ALK inhibitor medicine that did not work or is no longer working.

It is not known if KEYTRUDA is safe and effective in children less than 18 years of age.

PD-L1 = programmed death ligand 1;
EGFR = epidermal growth factor receptor;
ALK = anaplastic lymphoma kinase.

Ask Your Health Care Team if KEYTRUDA® (pembrolizumab) Is Right for You

Ask your health care team if KEYTRUDA is right for you

Want more info about KEYTRUDA?

Sign up for regular updates 

Need help talking to
your doctor?

Download a doctor
discussion guide 

For more information or to sign up over the phone, call 85-KEYTRUDA (855-398-7832)(855-398-7832).

Important Risk Information About KEYTRUDA® (pembrolizumab)

KEYTRUDA is a medicine that may treat your lung cancer by working with your immune system. KEYTRUDA® (pembrolizumab) can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.

Call or see your doctor right away if you develop any symptoms of the following problems or these symptoms get worse:

Lung problems (pneumonitis). Symptoms of pneumonitis may include shortness of breath, chest pain, or new or worse cough.

Intestinal problems (colitis) that can lead to tears or holes in your intestine. Signs and symptoms of colitis may include diarrhea or more bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; or severe stomach-area (abdomen) pain or tenderness.

Liver problems (hepatitis). Signs and symptoms of hepatitis may include yellowing of your skin or the whites of your eyes, nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine, feeling less hungry than usual, or bleeding or bruising more easily than normal.

Hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas). Signs and symptoms that your hormone glands are not working properly may include rapid heartbeat, weight loss or weight gain, increased sweating, feeling more hungry or thirsty, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, muscle aches, dizziness or fainting, or headaches that will not go away or unusual headache.

Kidney problems, including nephritis and kidney failure. Signs of kidney problems may include change in the amount or color of your urine.

Problems in other organs. Signs of these problems may include rash, changes in eyesight, severe or persistent muscle or joint pains, severe muscle weakness, or low red blood cells (anemia).

Infusion (IV) reactions, that can sometimes be severe and life-threatening. Signs and symptoms of infusion reactions may include chills or shaking, shortness of breath or wheezing, itching or rash, flushing, dizziness, fever, or feeling like passing out.

Getting medical treatment right away may help keep these problems from becoming more serious. Your doctor will check you for these problems during treatment with KEYTRUDA. Your doctor may treat you with corticosteroid or hormone replacement medicines. Your doctor may also need to delay or completely stop treatment with KEYTRUDA if you have severe side effects.

Before you receive KEYTRUDA, tell your doctor if you have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus; have had an organ transplant; have lung or breathing problems; have liver problems; or have any other medical problems.

If you are pregnant or plan to become pregnant, tell your doctor. KEYTRUDA can harm your unborn baby. Females who are able to become pregnant should use an effective method of birth control during treatment and for at least 4 months after the final dose of KEYTRUDA. Tell your doctor right away if you become pregnant during treatment with KEYTRUDA.

If you are breastfeeding or plan to breastfeed, tell your doctor. It is not known if KEYTRUDA passes into your breast milk. Do not breastfeed during treatment with KEYTRUDA and for 4 months after your final dose of KEYTRUDA.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Common side effects of KEYTRUDA include feeling tired, itching, diarrhea, decreased appetite, rash, shortness of breath, constipation, and nausea.

These are not all the possible side effects of KEYTRUDA. Tell your doctor if you have any side effect that bothers you or that does not go away. For more information, ask your doctor or pharmacist.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.

Please read the accompanying Medication Guide for KEYTRUDA® (pembrolizumab) and discuss it with your doctor. The physician Prescribing Information also is available.

E-mail a friend

Share this website about a treatment option for advanced non–small cell lung cancer. No personal information (including e-mail addresses) about you or your friend will be collected from this e-mail notification feature offered by Merck.